Very Low PSA Concentrations and Deletions of the KLK3 Gene

Santiago Rodriguez*, Osama A. Al-Ghamdi, Kimberley Burrows, Philip A. I. Guthrie, J. Athene Lane, Michael Davis, Gemma Marsden, Khalid K. Alharbi, Angela Cox, Freddie C. Hamdy, David E. Neal, Jenny L. Donovan, Ian N. M. Day

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

9 Citations (Scopus)

Abstract

BACKGROUND: Prostate-specific antigen (PSA), a widely used biomarker for prostate cancer (PCa), is encoded by a kallikrein gene (KLK3, kallikrein-related peptidase 3). Serum PSA concentrations vary in the population, with PCa patients generally showing higher PSA concentrations than control individuals, although a small proportion of individuals in the population display very low PSA concentrations. We hypothesized that very low PSA concentrations might reflect gene-inactivating mutations in KLK3 that lead to abnormally reduced gene expression.

METHODS: We have sequenced all KLK3 exons and the promoter and searched for gross deletions or duplications in KLK3 in the 30 individuals with the lowest observed PSA concentrations in a sample of approximately 85 000 men from the Prostate Testing for Cancer and Treatment (ProtecT) study. The ProtecT study examines a community-based population of men from across the UK with little prior PSA testing.

RESULTS: We observed no stop codons or frameshift mutations, but we did find 30 single-base genetic variants, including 3 variants not described previously. These variants included missense variants that could be functionally inactivating and splicing variants. At this stage, however, we cannot confidently conclude whether these variants markedly lower PSA concentration or activity. More importantly, we identified 3 individuals with different large heterozygous deletions that encompass all KLK3 exons. The absence of a functional copy of KLK3 in these individuals is consistent with their reduced serum PSA concentrations.

CONCLUSIONS: The clinical interpretation of the PSA test for individuals with KLK3 gene inactivation could lead to false-negative PSA findings used for screening, diagnosis, or monitoring of PCa. (C) 2012 American Association for Clinical Chemistry

Original languageEnglish
Pages (from-to)234-244
Number of pages11
JournalClinical Chemistry
Volume59
Issue number1
DOIs
Publication statusPublished - Jan 2013

Structured keywords

  • BTC (Bristol Trials Centre)
  • Centre for Surgical Research

Keywords

  • PROSTATE-SPECIFIC ANTIGEN
  • CANCER SUSCEPTIBILITY
  • POLYMORPHISMS
  • ASSOCIATION
  • PROMOTER
  • KALLIKREINS
  • POPULATION
  • VARIANTS
  • RECEPTOR
  • LOCUS

Cite this